Stock Analysts

Interpublic (IPG) Beats Q4 Earnings on Modest Organic Growth

The Interpublic Group of Companies, Inc. IPG reported fourth-quarter 2017 GAAP earnings of $316.6 million or 81 cents per share, slightly down from $317.6 million or 78 cents per share in the year-earlier quarter. The year-over-year increase in earnings per share despite lower net income was primarily due to lower outstanding shares due to share repurchases […]

Stock Analysts

Paycom (PAYC) Announces Amendment of Share Buyback Program

Paycom Software ’s PAYC board of directors recently declared amendment of its ongoing share repurchase program. The company will add $100 million of funds to the continuing buyback program and extend its duration till Feb 12, 2020. In May 2016, the company announced a plan to buy back shares worth $50 million over a span of 24 months. […]

Stock Analysts

Will Cost Saving Plans Support Coca-Cola’s (KO) Q4 Earnings?

The Coca-Cola Company KO is slated to report fourth-quarter 2017 results on Feb 16, before the opening bell. A Look at Coca-Cola’s Revenue Performance Coca-Cola has been struggling to boost sales amid weak demand in certain emerging and developing markets, and shift in consumer preference. The company has been witnessing a decline in revenues for the last 10 quarters, primarily due to weak volumes especially in the sparkling beverage category, and structural changes […]

Economic Data

Weak CPI, Retail Sales Weigh On Sentiments

What started off as another pleasing up market following a mild positive close on Tuesday turned into a blood-red market index in futures ahead of the bell this Valentine’s Day (Happy Valentine’s Day, by the way). What happened? New January Consumer Price Index (CPI) and Retail Sales numbers hit the tape […]

Stock Analysts

Teva Stock Falls as Novartis Brings Another Copaxone Generic

Shares of Teva Pharmaceutical Industries Limited TEVA were down around 4% on Tuesday, as another generic version of its blockbuster multiple sclerosis injection, Copaxone was launched earlier than expected. Sandoz – Novartis’ NVS generic arm – announced the FDA approval and launch of Glatopa 40 mg/ml, its generic version of 40 mg formulation of Copaxone. […]

Stock Analysts

Molson Coors (TAP) Q4 Earnings & Sales Rise Y/Y; Stock Gains

Molson Coors Brewing Company TAP reported fourth-quarter 2017 results, wherein both the top and bottom line improved year over year and the latter also beat the Zacks Consensus Estimate. Further, the company exceeded its cost-savings target for the year, encouraging management to raise its three-year target for 2019. The solid results helped this Zacks Rank #3 (Hold) stock gain 2.7% in the pre-market trading hours. […]

Stock Analysts

Lilly’s Taltz Positive in Phase III Label Expansion Study

Eli Lilly and Company LLY announced positive top-line data from a phase III label expansion study evaluating its psoriasis drug, Taltz (ixekizumab), in patients with ankylosing spondylitis (“AS”). The drug met the primary endpoint of improvement in the signs and symptoms of AS and all secondary endpoints as well. Taltz, an IL-17A antagonist, is currently approved for the treatment of adults with moderate-to-severe plaque psoriasis or active psoriatic arthritis (PsA) […]

Stock Analysts

Will Strong Product Adoption Drive IPG’s (IPGP) Q4 Earnings?

IPG Photonics IPGP is set to report fourth-quarter 2017 results on Feb 16. Notably, the company’s earnings have outpaced the Zacks Consensus Estimate in all the trailing four quarters, with an average positive surprise of 14.7%. In the last quarter, IPG reported earnings of $2.11 per share, beating the Zacks Consensus Estimate by 32 cents and advancing 64.1% year over year. […]